PLA2G7 and coronary artery disorder: Darapladib, a selective Lp-PLA2 inhibitor, in both clinical trials and animal studies reduced the necrotic core volume and arterial lesions but did not reduce the rate of cardiovascular death, myocardial infarction, or stroke in patients with stable CHD [62–64].